ClinPro Expands Business Development and Medical Affairs Teams
ClinPro, Inc., a full-service clinical research organization (CRO), today announced the expansion of its business development and medical affairs divisions with the appointment of Jeffrey Yablon as director, business development, Matthew Stannard as senior manager of business development and Linda Brown as senior project manager.
BOUND BROOK, NJ (May 12, 2005) -- ClinPro, Inc., a full-service clinical research organization (CRO), today announced the expansion of its business development and medical affairs divisions with the appointment of Jeffrey Yablon as director, business development, Matthew Stannard as senior manager of business development and Linda Brown as senior project manager.
"We're pleased to have such a talented and experienced group join ClinPro," said Rich Purcell, president of ClinPro, Inc. "Each new team member will play a pivotal role in ClinPro's mission of providing high-quality and cost-effective clinical trial management solutions."
As director, business development of ClinPro, Inc., Mr. Yablon brings a wealth of experience from the pharmaceutical, healthcare and clinical trials industries. In his new role, Mr. Yablon will identify new business opportunities, consult on clinical development strategy, and assist with corporate planning. In addition, he will prepare proposals, budget estimates and secure new contracts with companies in the drug development and medical device communities.
Most recently, Mr. Yablon was the chief operating officer for ICON Laboratories where he managed global operations for their central clinical trials laboratory and oversaw over 450 employees. In addition, he created new business opportunities that included pharmacogenomics and immunology businesses, and supervised the construction and development of ICON's new $25 million headquarters. Mr. Yablon holds an MBA from Fairleigh Dickinson University.
As senior manager of business development, Mr. Stannard is responsible for the development of ClinPro's new business opportunities, sales operations and strategic planning. Prior to his new position, Mr. Stannard spent six years in ClinPro's Clinical Operations Group where he managed several clinical trials, spending the latter portion of his years as Clinical Project Manager.
Mr. Stannard began his career as an analytical chemist where he received extensive hands-on experience in the development of several new drug entities. Mr. Stannard holds a B.A. in Molecular Biology from Lehigh University.
As senior project manager, Ms. Brown will oversee clinical development projects, and manage the day-to-day logistics of conducting clinical trials. She will be the primary point person for communications among our sponsors, investigators, and ClinPro staff, especially for studies in ClinPro's Center for Oncology Research Management (CORM).
Before joining ClinPro, Ms. Brown spent her 20-year career in a variety of roles in the pharmaceutical and biotechnology industries concentrating on project management, corporate communications, and clinical research. In addition, Ms. Brown has played a significant role in numerous product launches and marketing initiatives. Ms. Brown holds a B.A. in Biology from Gettysburg College.
ABOUT CLINPRO, INC.
ClinPro, Inc. is a growing, independent, full-service clinical research organization (CRO) with expertise in a variety of therapeutic areas. For more information on ClinPro's clinical trial services and expertise, contact ClinPro at (732) 868-0200. For media inquiries, contact Candace Vadnais at PFS Marketwyse (973) 812-8883, ext. 430 or visit ClinPro's Web site at www.clinproinc.com . ticlebody>
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
